Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,403 across all filing types
Latest filing 2023-12-19 Regulatory Filings
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated December 19, 2023, announcing that Sanofi exercised a license option for a new NK Cell Engager program from Innate Pharma, involving a €15 million payment to Innate. This type of announcement, detailing a specific business transaction, licensing event, or material development that is not a full financial report (like 10-K or IR), typically falls under a general regulatory announcement or a specific corporate action category. Since it details a significant financial/strategic agreement (licensing option exercise and associated payment/milestones), it relates to capital structure changes or financing activities, but more broadly, it is a corporate disclosure. Given the options, this is a material corporate event announcement. It is not an Earnings Release (ER), Interim Report (IR), or a formal regulatory filing like 10-K. It is a specific announcement about a partnership milestone. The closest fit among the provided codes for a significant, non-financial-statement corporate event announcement that doesn't fit other specific categories (like M&A, Director Dealing, Dividend) is often the general Regulatory Filings (RNS) or potentially Capital/Financing Update (CAP) if the focus was purely on the cash inflow/option structure. However, since it is a detailed press release announcing a specific business development (licensing option exercise), and it is not a short notice of publication (ruling 2), it is best classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP). Given the context of a biotech licensing deal, RNS serves as the best general regulatory announcement category when a more specific one like TAR (M&A) doesn't apply. I will lean towards RNS as the most appropriate general regulatory disclosure for this type of corporate news.
2023-12-19 French
INNATE PHARMA S.A. 6-K
Foreign Filer Report
2023-12-18 English
Inside Information / Other news releases
Board/Management Information Classification · 1% confidence The document is titled "INNATE PHARMA ANNOUNCES LEADERSHIP CHANGE" and details the resignation of the CEO and the appointment of an interim CEO and a new Chairwoman of the Supervisory Board. This content directly corresponds to the definition of Board/Management Information, which covers announcements of changes in the company's board of directors or senior management. The filing type code for this is MANG.
2023-12-18 English
Informations privilégiées / Autres communiqués
Board/Management Information Classification · 1% confidence The document is titled "INNATE PHARMA ANNONCE UN CHANGEMENT DE DIRECTION" (Innate Pharma Announces a Change in Management) and details the resignation of the Chairman of the Management Board (Mondher Mahjoubi) and subsequent appointments of interim and supervisory board leadership. This content directly relates to changes in the company's senior management team. According to the definitions, this aligns perfectly with the Board/Management Information category.
2023-12-18 French
INNATE PHARMA S.A. 6-K
Foreign Filer Report
2023-12-11 English
INNATE PHARMA S.A. 6-K
Foreign Filer Report
2023-12-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.